BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chok KS. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015; 7(8): 1142-1148 [PMID: 26052403 DOI: 10.4254/wjh.v7.i8.1142] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Qi X, Li G, Liu D, Motamarry A, Huang X, Wolfe AM, Helke KL, Haemmerich D, Staveley-O'Carroll KF, Kimchi ET. Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer. Cancer Biol Ther 2015;16:1812-9. [PMID: 26537481 DOI: 10.1080/15384047.2015.1095412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hafezi M, Tan A, Bertoletti A. Personalized Armored TCR-Redirected T Cell Therapy for Liver/Organ Transplant with Recurrent Cancer. Cells 2021;10:1861. [PMID: 34440630 DOI: 10.3390/cells10081861] [Reference Citation Analysis]
3 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
4 Ma KW, Cheung TT. When to consider liver transplantation in hepatocellular carcinoma patients? Hepat Oncol. 2017;4:15-24. [PMID: 30191050 DOI: 10.2217/hep-2016-0010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Lim LJ, Ling LH, Neo YP, Chung AYF, Goh BKP, Chow PKH, Chan CY, Cheow PC, Lee SY, Lim TKH, Chong SS, Ooi LLPJ, Lee CG. Highly deregulated lncRNA LOC is associated with overall worse prognosis in Hepatocellular Carcinoma patients. J Cancer 2021;12:3098-113. [PMID: 33976720 DOI: 10.7150/jca.56340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ji Y, Zhu J, Zhu L, Zhu Y, Zhao H. High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases. Front Oncol 2020;10:519164. [PMID: 33194582 DOI: 10.3389/fonc.2020.519164] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Zhang JA, Kwee SA, Wong LL. Late recurrence of hepatocellular carcinoma after liver transplantation. Hepatoma Res 2017;3:58-66. [PMID: 28966983 DOI: 10.20517/2394-5079.2017.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
8 Ekpanyapong S, Philips N, Loza BL, Abt P, Furth EE, Tondon R, Khungar V, Olthoff K, Shaked A, Hoteit MA, Reddy KR. Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience. J Clin Exp Hepatol 2020;10:304-15. [PMID: 32655233 DOI: 10.1016/j.jceh.2019.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Kim SS, Kang TW, Song KD, Cho SK, Lee MW, Rhim H, Sinn DH, Jung SH. Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. Clin Radiol 2017;72:141-9. [PMID: 27742104 DOI: 10.1016/j.crad.2016.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
10 Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol 2018; 24(45): 5081-5094 [PMID: 30568386 DOI: 10.3748/wjg.v24.i45.5081] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
11 Simsek C, Kim A, Ma M, Danis N, Gurakar M, Cameron AM, Philosophe B, Garonzik-Wang J, Ottmann S, Gurakar A, Saberi B. Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series. Hepatoma Res 2020;6:11. [PMID: 32582866 DOI: 10.20517/2394-5079.2019.51] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Au KP, Dai WC, Chi-Yan Chan A, Cheung TT, Lo CM, Chok KS. Performance of Dual-tracer PET-CT for Staging Post-Liver Transplant Hepatocellular Carcinoma Recurrence. Transplant Direct 2021;7:e769. [PMID: 34557586 DOI: 10.1097/TXD.0000000000001213] [Reference Citation Analysis]
13 Au KP, Chiang CL, Chan ACY, Cheung TT, Lo CM, Chok KSH. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation. World J Clin Cases 2020; 8(13): 2758-2768 [PMID: 32742986 DOI: 10.12998/wjcc.v8.i13.2758] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Shaw BI, Lucander A, Ravindra KV. Very Late Recurrence of Hepatocellular Carcinoma After Orthotopic Liver Transplantation: Presentation and Management. Transplant Direct 2019;5:e483. [PMID: 31579811 DOI: 10.1097/TXD.0000000000000921] [Reference Citation Analysis]
15 Lin YJ, Ho CM. Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review. Medicina (Kaunas) 2021;57:131. [PMID: 33540784 DOI: 10.3390/medicina57020131] [Reference Citation Analysis]
16 Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1617. [PMID: 33807392 DOI: 10.3390/cancers13071617] [Reference Citation Analysis]
17 de'Angelis N, Landi F, Nencioni M, Palen A, Lahat E, Salloum C, Compagnon P, Lim C, Costentin C, Calderaro J. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. Prog Transplant. 2016;. [PMID: 27555074 DOI: 10.1177/1526924816664083] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
18 Yang W, Wu H, Zhang Z, Lee J, Wang S, Wang Y, Wu W, Chen M, Yan K. Long-term outcome of percutaneous radiofrequency ablation in recurrent hepatocellular carcinoma after liver transplantation. International Journal of Hyperthermia 2018;34:68-76. [DOI: 10.1080/02656736.2017.1324179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Kim M, Kang TW, Jeong WK, Kim YK, Kim SH, Kim JM, Sinn DH, Kim M, Jung S. Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants. Eur Radiol 2017;27:3117-27. [DOI: 10.1007/s00330-016-4662-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]